Clinical Trials Sponsored by Novartis+Pharmaceuticals

Total 21557 results

Novartis Pharmaceuticals

Completed

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)

Allergic Asthma

Japan
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients. (BENEFIT)

Type 2 Diabetes Mellitus

Germany
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland
Novartis Pharmaceuticals

Completed

Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients

De Novo Renal Transplantation

Norway
Novartis Pharmaceuticals

Completed

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol (REVERBREZ)

Chronic Obstructive Pulmonary Disease (COPD)

France
Novartis Pharmaceuticals

Terminated

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

Familial Chylomicronemia Syndrome (FCS) (HLP Type I)

South Africa, Germany, United Kingdom, France, United States, Canada, Netherlands
Novartis Pharmaceuticals

Completed

Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects

Atopic Asthma

Germany, Italy, Spain, Netherlands, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma (PANORAMA-5)

Multiple Myeloma
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Novartis Pharmaceuticals

Completed

Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRYSTAL)

Central Retinal Vein Occlusion | Macular Edema

Greece, Hungary, Turkey, Australia, Austria, Netherlands, United Kingdom, Italy, Spain, Ireland, Portugal, Slovakia, Canada, Switzerland, Czech Republic, Poland, Denmark, Sweden
Novartis Pharmaceuticals

Completed

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans (ATLAAST)

Hypertension

United States
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain

Post Operative Dental Pain

United States
Novartis Pharmaceuticals

Withdrawn

Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients

Familial Hypercholesterolemia
Novartis Pharmaceuticals

Completed

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. (EVOLVE-1)

Carcinoma

China, Italy, Taiwan, Germany, Hungary, Belgium, Spain, Australia, Austria, France, Hong Kong, Thailand, Korea, Republic of, Canada, Japan, Israel, United States, Greece
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Chronic Spontaneous Uriticaria

Korea, Republic of, Japan
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany, Australia, Hong Kong, Switzerland, Spain, France, United States
Novartis Pharmaceuticals

Terminated

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Metastatic Breast Cancer | HER2+ Breast Cancer

Belgium, France, Spain, United States, United Kingdom, Italy
Novartis Pharmaceuticals

Completed

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL) (PATH)

Hodgkin's Lymphoma

United States, Belgium, Germany, Canada, Singapore, Netherlands, France, Australia, Russian Federation, Israel, Brazil, Italy, New Zealand, Poland
Novartis Pharmaceuticals

Completed

A Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)

Gastrointestinal Stromal Tumor (GIST)

China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
Novartis Pharmaceuticals

Completed

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Multiple Sclerosis | Relapsing-Remitting

Turkey
Novartis Pharmaceuticals

Completed

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma (RECORD-4)

Metastatic Renal Cell Carcinoma

China, Argentina, Brazil, Russian Federation, Bulgaria, United States
Novartis Pharmaceuticals

Terminated

Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

Fragile X Syndrome

Germany, United States, Switzerland, Australia, Canada, Denmark, France, Italy, United Kingdom, Spain
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Novartis Pharmaceuticals

Terminated

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (PACE)

Fatigue in Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Terminated

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

Bullous Pemphigoid

Taiwan, Germany, United States, Japan, Austria, France
Novartis Pharmaceuticals

Completed

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin (ADDONIS)

Type 2 Diabetes Mellitus (T2DM)

France
Novartis Pharmaceuticals

Terminated

Effect of AQW051 in Patients With Memory Impairment

Amnestic Mild Cognitive Impairment | Mild Alzheimer's Disease

Canada, United Kingdom, South Africa
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors (pNET)

United Kingdom, Spain, Netherlands, Italy, Russian Federation, France, Switzerland, United States
Novartis Pharmaceuticals

Terminated

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

AML | cKIT-positive Solid Tumors

Belgium, Spain, Australia, Netherlands
Novartis Pharmaceuticals

Terminated

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)

Primary Myelofibrosis

Spain, Germany, Italy
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Renal Transplant Patients With And Without Gastrointestinal (GI) Symptoms (PROGIS)

Kidney Transplantation | GI Symptoms Severity

Malaysia
Novartis Pharmaceuticals

Completed

A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374

Healthy Subjects

United Kingdom
Novartis Pharmaceuticals

Completed

Intra-venous Zoledronic Acid Once Yearly (IVORY)

Post-Menopausal Osteoporosis

Canada
Novartis Pharmaceuticals

Terminated

38 Week Extension Study to CAIN457C2303 (SHIELD)

Uveitis

Turkey, Spain, France, Israel, Germany, Greece, Korea, Republic of, Hong Kong, United States, Egypt, Jordan, Singapore, Taiwan, Tunisia
Novartis Pharmaceuticals

Completed

Imatinib (QTI571) in Pulmonary Arterial Hypertension (IMPRES)

Pulmonary Arterial Hypertension

United States, Switzerland, Germany, Belgium, Spain, United Kingdom, Italy, Korea, Republic of, Netherlands, Canada, Sweden, Austria, Japan, France
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib (MACS1428)

Chronic Myelogenous Leukemia in Chronic Phase

United States
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Novartis Pharmaceuticals

Completed

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Transfusional Hemosiderosis

Egypt, Spain, United Kingdom, Jordan
Novartis Pharmaceuticals

Completed

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Psoriasis, Plaque-type Psoriasis

United States
Novartis Pharmaceuticals

Terminated

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) (MONALEESA-1)

Early Breast Cancer

Spain, Singapore, United States
Novartis Pharmaceuticals

Completed

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM)

Melanoma

United States, Belgium, Germany, Singapore, Italy, Australia, Netherlands, Sweden, Spain, Canada, Switzerland, Argentina, Brazil, China
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

South Africa, Belgium, Germany, Australia, Netherlands, Bulgaria, Austria, Romania
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Hypertension

United States, Spain, Philippines, Guatemala, Russian Federation, Argentina, Puerto Rico
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Asthma

Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
Novartis Pharmaceuticals

Completed

Ext. Long-term Safety Study in CF Patients: Single Arm TIP

Long-term Safety of TIP

Italy, Spain, Germany, United States, Australia, Canada, Hungary, Mexico, Argentina
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia

Pre-eclampsia

Italy, United States

Clinical Trials Sponsored by Novartis+Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations